Literature DB >> 30661832

Partial protection induced by Salmonella based Brucella vaccine candidate in pregnant guinea pigs.

Jonathan Lalsiamthara1, Amal Senevirathne1, John Hwa Lee2.   

Abstract

Residual virulence is a major drawback in current Brucella vaccines. Live vaccines induce abortions in pregnant animals. Hence, a novel anti-Brucella vaccine was developed utilizing rough Salmonella delivering four Brucella antigens. Safety implications during pregnancy, humoral immune responses, and protective efficacy against wild type Brucella was investigated in guinea pig model. The vaccine did not induce abortions or severe complications in pregnant guinea pigs when administered 4 × 108 CFU via intraperitoneal route. Systemic IgG determination against antigen components reveals induction of immunity via the Salmonella delivery. Protection efficacy against abortions was 33.3% (2/6) when midterm sow challenged with virulent Brucella 544 strain while none was protected in control group. Lower Brucella recovery in spleen and liver and reduced histopathological burden were also noticed. Although abortion induced by Brucella challenge was not completely prevented, the vaccine candidate may perform better with optimization of vaccination such as inoculation dose optimization.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Abortion; Brucella vaccine; Brucellosis; Pregnant guinea pig model; Rough Salmonella vaccine vector

Mesh:

Substances:

Year:  2019        PMID: 30661832     DOI: 10.1016/j.vaccine.2019.01.020

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Evaluation of the Efficacy of the Brucella canis RM6/66 ΔvjbR Vaccine Candidate for Protection against B. canis Infection in Mice.

Authors:  Daniel G Garcia-Gonzalez; Omar H Khalaf; Lauren W Stranahan; Sankar P Chaki; Angela M Arenas-Gamboa
Journal:  mSphere       Date:  2020-05-20       Impact factor: 4.389

Review 2.  Immune Response to Mucosal Brucella Infection.

Authors:  Rubén López-Santiago; Ana Beatriz Sánchez-Argáez; Liliana Gabriela De Alba-Núñez; Shantal Lizbeth Baltierra-Uribe; Martha Cecilia Moreno-Lafont
Journal:  Front Immunol       Date:  2019-08-20       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.